Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.60 |
| ▸ | DRD4 | P21917 | 11/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038410 | 1.00 | SLC6A2 (0.60) | SLC6A2DRD4DRD2DRD3MEN1 | |
| SCHEMBL14595287 | 1.00 | SLC6A2 (0.60) | SLC6A2DRD4DRD2DRD3MEN1 | |
| SCHEMBL14202986 | 1.00 | SLC6A2 (0.60) | SLC6A2DRD4DRD2DRD3MEN1 | |
| SCHEMBL14203018 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL5043878 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL14203001 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL5038423 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL8292652 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL14595291 | 0.91 | SLC6A2 (0.51) | SLC6A2DRD4SIGMAR1 | |
| SCHEMBL5671331 | 0.91 | DRD4 (0.50) | SLC6A2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |